182 related articles for article (PubMed ID: 19036180)
1. EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
Okuyucu EE; Guven O; Duman T; Gorur S; Melek IM; Akcin S; Yilmazer S
Neurol Res; 2009 Apr; 31(3):313-5. PubMed ID: 19036180
[TBL] [Abstract][Full Text] [Related]
2. [The safety of tadalafil in the treatment of erectile dysfunction].
Wang HY; Huang YF
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):762-4. PubMed ID: 17918720
[TBL] [Abstract][Full Text] [Related]
3. [Tadalafil for erectile dysfunction: excellent safety and tolerance].
Bai WJ
Zhonghua Nan Ke Xue; 2009 Jan; 15(1):92-5. PubMed ID: 19288756
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy, safety and perspectives of tadalafil in a long-term once a day regimen in patients with erectile dysfunction].
Zhivov AV
Urologiia; 2009; (6):75-7. PubMed ID: 20175281
[No Abstract] [Full Text] [Related]
7. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil (Cialis) for erectile dysfunction.
Noviasky JA; Masood A; Lo V
Am Fam Physician; 2004 Jul; 70(2):359-60. PubMed ID: 15291094
[No Abstract] [Full Text] [Related]
9. [Observation of safety and efficacy of tadalafil for men with erectile dysfunction].
Zhu XW; Li FY; Fang JJ
Zhonghua Nan Ke Xue; 2006 May; 12(5):421-3, 427. PubMed ID: 16755872
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
Montorsi F; Verheyden B; Meuleman E; Jünemann KP; Moncada I; Valiquette L; Casabé A; Pacheco C; Denne J; Knight J; Segal S; Watkins VS
Eur Urol; 2004 Mar; 45(3):339-44; discussion 344-5. PubMed ID: 15036680
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil (Cialis) once a day for erectile dysfunction.
Med Lett Drugs Ther; 2008 Apr; 50(1283):27-8. PubMed ID: 18391900
[No Abstract] [Full Text] [Related]
13. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Porst H; Hell-Momeni K; Büttner H
Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.
Gaines KK
Urol Nurs; 2004 Feb; 24(1):46-8. PubMed ID: 15054911
[No Abstract] [Full Text] [Related]
15. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C;
Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.
Incrocci L; Slagter C; Slob AK; Hop WC
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):439-44. PubMed ID: 16965992
[TBL] [Abstract][Full Text] [Related]
17. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
18. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Schiefer J; Sparing R
Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic dilemma: how to use tadalafil.
Carosa E; Lombardo F; Martini P; Brandetti F; Jannini EA
Int J Androl; 2005 Dec; 28 Suppl 2():74-80. PubMed ID: 16236070
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].
Calvet C; Martin K; Robert G; Moore N; Eftekhari P; Farghal H; Molimard M; Ballanger P
Prog Urol; 2007 Sep; 17(5):920-7. PubMed ID: 17969789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
